BiVictriX Therapeutics plc - Intention to float on AIM
News & Press
January 7, 2021
BiVictriX Therapeutics plc, the developer of targeted cancer therapies based on its novel Bi-Cygni® approach, announces its intention to apply for admission to trading on AIM a market operated by the London Stock Exchange plc.
View PDF Announcement
View Admission Document
Please submit the form below and we shall be in touch
* We don't share your data. See our
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
August 11, 2021
RNS - Admission to Trading on Aim and First Day of Dealings